Search
Citations & References (6)
Gibco™
CTS™ Synth-a-Freeze™ Medium
CTS™ (Cell Therapy Systems) Synth-a-Freeze™ medium is a chemically defined, protein-free liquid cryopreservation medium intended for freezing and storing a詳細を見る
| 製品番号（カタログ番号） | 数量 |
|---|---|
| A1371301 | 50 mL |
製品番号（カタログ番号） A1371301
価格（JPY）お問い合わせください ›
19,400
Each
数量:
50 mL
CTS™ (Cell Therapy Systems) Synth-a-Freeze™ medium is a chemically defined, protein-free liquid cryopreservation medium intended for freezing and storing a variety of mammalian cell types including stem cells. Synth-a-Freeze™ CTS™ media is optimally formulated without antibiotics, antimycotics, hormones, growth factors, serum, or protein and buffered with HEPES and sodium bicarbonate.
• Use for cryopreserving a variety of primary and stem cells
• Save time and effort with 4 degree stable storage of thawed media and compatibility with a variety freezing protocols
• Be ready for clinical research with this cGmP manufactured, chemically defined, protein-free formula
Cryopreserve a Variety of Cell Types
Cell Therapy Systems Synth-a-Freeze™ CTS™ media performs comparable to our standard, serum-containing cryopreservation medium for cryopreserving a variety of cell types including human Embryonic Stem Cells, Neural Stem Cells (Ref 1), Mesenchymal Stem Cells and Keratinocytes (Ref 2). We do not recommend using Synth-a-Freeze™ media for cryopreservation of human epidermal melanocytes.
Simple Incorporation into Your Current Freezing Protocol
Synth-a-Freeze™ CTS™ media can be used with any standard freezing protocol. Just add thawed Cell Therapy Systems Synth-a-Freeze™ CTS™ media to detached and pelleted cells, aliquot, and freeze. For optimal results, the use of a controlled-rate freezer is recommended.
Simplify Your Transition into Clinical Research
The Gibco™ Cell Therapy Systems (CTS™) brand offers a broad array of products for use in cell therapy applications, including media, reagents, growth factors, enzymes, cell selection/expansion reagents, and devices. Gibco™ Cell Therapy Systems (CTS™) products deliver:
• Reduced burden in qualifying reagents
• Included appropriate certificates of analyses and origin
• Convenient access to our Drug Master File (DMF)
For Research Use or Manufacturing of Cell, Gene, or Tissue-Based Products.
CAUTION: Not intended for direct administration into humans or animals
References:
• S. Shin and M. Vemuri. Culture and Differentiation of Human Neural Stem Cells. L.C. Doering (ed). Protocols for Neural Cell Culture. Springer Protocol Handbooks.
• S. Lemaire, K. Kosowska-Shick, P. Appelbaum, G. Verween, P. Tulkens, and F. Van Bambeke. Cellular Pharmacodynamics of the Novel Biaryloxazolidinone Radezolid: Studies with Infected Phagocytic and Nonphagocytic cells, Using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrob Agents Chemother 54(6) 2010: 2549-2559.
研究用途にのみご使用ください。診断目的には使用できません。
仕様
細胞タイプVarious (including types of human Embryonic Stem Cells, Neural Stem Cells, Mesenchymal Stem Cells, and Keratinocytes)
使用対象（アプリケーション）Cell and Gene Therapy Research, Development, and Manufacturing
フォーマットBottle
製造品質ISO 13485, MDSAP, FDA-registered, 21 CFR 820
製品タイプCryopreservation Medium
数量50 mL
品質保持期間18 months from date of manufacture
出荷条件Dry Ice
分類Animal Origin-free
形状Liquid
無菌性Sterile-filtered
添加剤ありDMSO (10%)
Unit SizeEach
組成および保存条件
Store at –20°C.
よくあるご質問（FAQ）
What is CTS?
If the Synth-a-Freeze Cryopreservation Medium is not suitable for melanocytes, how should I freeze melanocytes?
Is there a Drug Master File for the Synth-a-Freeze Cryopreservation Medium?
What can I use Synth-a-Freeze Cryopreservation Medium for?
Was the tissue cryopreserved prior to isolation of primary cells?
引用および参考文献 (6)
引用および参考文献
Abstract
Serum-free suspension culturing of human cells: adaptation, growth, and cryopreservation.
Journal:Bioprocess Biosyst Eng
PubMed ID:25822314
Human cell lines have attracted great interest because they are capable of producing glycosylated proteins that are more similar to native human proteins, thereby reducing the potential for immune responses. However, these cells have not been extensively characterized and cultured under serum-free suspension conditions. In this work, we describe the
Amnion epithelial cell isolation and characterization for clinical use.
Journal:Curr Protoc Stem Cell Biol
PubMed ID:20373516
Human amnion epithelial cells (hAECs) are a heterologous population positive for stem cell markers; they display multilineage differentiation potential, differentiating into cells of the endoderm (liver, lung epithelium), mesoderm (bone, fat), and ectoderm (neural cells). They have a low immunogenic profile and possess potent immunosuppressive properties. Hence, hAECs may be
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
Journal:Antimicrob Agents Chemother
PubMed ID:20385852
Radezolid is a novel biaryloxazolidinone in clinical development which shows improved activity, including against linezolid-resistant strains. In a companion paper (29), we showed that radezolid accumulates about 11-fold in phagocytic cells, with approximately 60% of the drug localized in the cytosol and approximately 40% in the lysosomes of the cells.
Rapid and Efficient Generation of Transgene-Free iPSC from a Small Volume of Cryopreserved Blood.
Journal:
PubMed ID:25951995
Human peripheral blood and umbilical cord blood represent attractive sources of cells for reprogramming to induced pluripotent stem cells (iPSCs). However, to date, most of the blood-derived iPSCs were generated using either integrating methods or starting from T-lymphocytes that have genomic rearrangements thus bearing uncertain consequences when using iPSC-derived lineages
Biological impact of xeno-free chemically defined cryopreservation medium on amniotic epithelial cells.
Journal:Stem Cell Res Ther
PubMed ID:26758986
'Amnion-derived stem cells have been proposed for cell replacement therapy and tissue regeneration. An easily accessible cell source, the placenta, allows us to potentially establish a bio-bank of cells for immunotype matched clinical applications. Several xeno-free (XF) cryopreservation media are currently available for pluripotent stem cells, however, these media have